United States Insulin Delivery Devices Market Report 2021

The United States Insulin Delivery Devices Market is expected to surpass US$ 10 billion by 2027.

The “United States Insulin Delivery Devices Market Size, Analysis, Insights, Trends, Share Outlook, Opportunities, Companies and Forecasts up to 2027” report has been added to ResearchAndMarkets.com’s offering.

The United States Insulin Delivery Devices Market is expected to surpass US$ 10 billion by 2027.

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends. The report presents the most up-to-date industry data on the actual and potential market situation and future outlook for insulin delivery devices in the United States.

The report also provides up-to-date historical market size data for the period 2019 – 2020 and an illustrative forecast to 2027 covering key market aspects like market value and volume for insulin delivery devices in the United States.

The United States insulin delivery devices market is one of the high-growth evolving industries with potential opportunities throughout 2027. The report delivers an all-around analysis of the overall number of patients with diabetes in the United States. Moreover, the report provides deep insights on type 1, type 2, and newly diagnosed type 1 diabetes patients’ data.

Additionally, this report provides overall insulin delivery devices users’ insights and up-to-date market size with more focus on their product categories such as Insulin Pump, Insulin Pen, Insulin Syringe, Insulin Inhaler, and Insulin Jet Injector.

Additionally, this up-to-date market report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States insulin delivery devices market. Key trends in terms of collaboration, partnership deals, licensing, and exclusive agreement are analyzed in detail. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the U.S insulin delivery devices market.

The report also analyses detailed profiles of innovative and leading players with information on business overview, product portfolio, and the latest developments.

Key Questions Addressed by the Report:

  • What is the current size of the overall insulin delivery devices market in the United States?
  • How much will this market be worth from 2021 to 2027?
  • How big is the United States insulin delivery devices market?
  • What is the total insulin delivery devices users volume in the United States?
  • What are the key marketed insulin delivery devices available in the United States?
  • What are the major drivers of the United States insulin delivery devices market?
  • What are the major inhibitors of the United States insulin delivery devices market?
  • What is the reimbursement pattern of the United States insulin delivery devices market?
  • What is the regulatory framework of the United States insulin delivery devices market?
  • Which companies make insulin delivery devices?
  • Who are the top market players? What are their happenings, current developments, and scenarios?

The Leading Companies for the United States Insulin Delivery Devices Market are Listed Below:

  • Medtronic
  • Tandem Diabetes Care
  • Insulet Corporation
  • Sooil Development
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Owen Mumford
  • Companion Medical
  • Diabnext
  • Digital Medics Pty Ltd.
  • Emperra GmbH E-Health Technologies
  • Diamesco Co., Ltd.
  • Becton, Dickinson, and Company (BD)
  • Abbott Diabetes Care
  • Smith’s Medical, Inc.
  • Arkray, Inc
  • Trividia Health, Inc
  • MHC Medical Products, LLC
  • Home Aide Diagnostics, Inc
  • Advocate Meters (Pharma Supply, Inc.)
  • Retractable Technologies, Inc.
  • Prodigy Diabetes Care, LLC
  • UltiMed, Inc
  • AdvaCare Pharma USA, LLC
  • Allison Medical, Inc
  • Cardinal Health, Inc
  • MannKind Corporation
  • Insujet

Key Topics Covered:

1. Executive Summary

2. United States Diabetes Population (2019 – 2027): An Analysis
2.1 Overall Diabetes Population
2.1.1 Type 1 Diabetes
2.1.2 Type 2 Diabetes
2.1.3 Newly Diagnosed Type 1 Diabetes

3. United States Insulin Delivery Devices Users Analysis (2019 – 2027)
3.1 Overall Insulin Delivery Users Snapshot
3.2 Insulin Pump Users
3.2.1 Type 1 Diabetes Insulin Pump Users
3.2.2 Type 2 Diabetes Insulin Pump Users
3.3 Insulin Pen Users
3.3.1 Reusable (Cartridge) Insulin Pen Users
3.3.2 Prefilled (Disposable) Insulin Pen Users
3.3.3 Smart Insulin Pen Users
3.4 Insulin Pen Segment – (Reusable, Prefilled, Smart Insulin Pen) Users Share
3.5 Insulin Syringe Users
3.6 Insulin Inhaler Users
3.7 Insulin Jet Injector Users

4. United States Insulin Delivery Devices Market Size and Forecast (2019 – 2027)
4.1 Overall Insulin Delivery Devices Market Snapshot
4.2 Insulin Delivery Devices Segment – (Insulin Pump, Insulin Pen, Insulin Syringe, Insulin Inhaler, Insulin Jet Injector) Market Share
4.3 Insulin Pump Market Size
4.4 Insulin Pen Market Size
4.4.1 Reusable (Cartridge) Insulin Pen Market
4.4.2 Prefilled (Disposable) Insulin Pen Market
4.4.3 Smart Insulin Pen Market
4.5 Insulin Pen Segment – (Reusable, Prefilled and Smart Insulin Pen) Market Share
4.6 Insulin Syringe Market Size
4.7 Insulin Inhaler Market Size
4.8 Insulin Jet Injector Market Size

5. Key Market Growth Drivers and Challenges of the United States Insulin Delivery Devices Market
5.1 Market Growth Drivers
5.2 Market Challenges

6. Regulatory Framework of the United States Insulin Delivery Devices Market

7. Reimbursement Environment of the United States Insulin Delivery Devices Market
7.1 Insulin Pump
7.2 Insulin Pen
7.3 Insulin Syringe
7.4 Insulin Inhaler
7.5 Insulin Jet Injector

8. Major Deals Happening in the Insulin Delivery Devices Market
8.1 Collaboration Deals
8.2 Licensing Agreement
8.3 Exclusive Agreement
8.4 Partnerships Deal

9. Key Companies Analysis
9.1 Business Overview
9.2 Product Portfolios
9.3 Latest Development

For more information about this report visit here.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.